[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.

DocumentFichier
Fichier pdf chargé le 29/01/2015 à 11:08:29

(version éditeur)
fichier
Titre[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.
Type de publicationArticle de revue
AuteurHachemi, Mammar , Couturier, Olivier-François
1, 2
, Vervueren, Laurent , Fosse, Pacôme , Lacœuille, Franck
1, 2
, Urban, Thierry
1, 2
, Hureaux, José
1, 2
EditeurPublic Library of Science
TypeArticle scientifique dans une revue à comité de lecture
Année2014
LangueAnglais
Date2014
Paginatione87629
Volume9
Titre de la revuePLoS One
ISSN1932-6203
Mots-clésAdult, Aged, Carcinoma, Non-Small-Cell Lung, Disease-Free Survival, Female, Fluorodeoxyglucose F18, Humans, Lung Neoplasms, Male, Middle Aged, Positron-Emission Tomography, Protein Kinase Inhibitors, Quinazolines, Radiopharmaceuticals, Survival rate, Time Factors
Résumé en anglais

PURPOSE: The aim of this prospective study was to evaluate whether [¹⁸F]FDG-PET/CT, performed within two weeks of starting erlotinib therapy can predict tumor response defined by RECIST 1.1 criteria after 8 weeks of treatment in patients with inoperable (stage IIIA to IV) non-small cell lung cancer patients.

PATIENTS AND METHODS: Three [¹⁸F]FDG-PET/CT scans were acquired in 12 patients before (5±4 days) and after 9±3 days (early PET) and 60±6 days (late PET) of erlotinib therapy. Conventional evaluation, including at least chest CT (baseline versus after 8 weeks of treatment), was performed according to RECIST 1.1 criteria. Change in [¹⁸F]FDG uptake was compared with conventional response, progression-free survival (PFS), and overall survival (OS).

RESULTS: By using ROC analysis, the Area Under the Curve for prediction of metabolic non-progressive disease (mNP) by early PET was 0.86 (95% CI, 0.62 to 1.1; P = 0.04) at a cut-off of 21.6% reduction in maximum Standardized Uptake Value (SUVmax). This correctly classified 11/12 patients (7 with true progressive disease; 4 with true non-progressive disease; 1 with false progressive disease). Non-progressive disease after 8 weeks of treatment according to RECIST 1.1 criteria was significantly more frequent in patients classified mNP (P = 0.01, Fisher's exact test). mNP patients showed prolonged PFS (HR = 0.27; 95% CI, 0.04 to 0.59; P<0.01) and OS (HR = 0.34; 95% CI, 0.06 to 0.84; P = 0.03). Late PET analysis provided concordant results.

CONCLUSION: Morphologic response, PFS and OS survival in non-small cell lung cancer patients can be predicted by [¹⁸F]FDG-PET/CT scan within 2 weeks after starting erlotinib therapy.

URL de la noticehttp://okina.univ-angers.fr/publications/ua7162
DOI10.1371/journal.pone.0087629
Lien vers le document

http://dx.doi.org/10.1371/journal.pone.0087629

Autre titrePLoS ONE
Identifiant (ID) PubMed24505298